Gilead Sciences
(NQ:
GILD
)
76.77
+0.28 (+0.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
November 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In...
Via
Benzinga
Exposures
COVID-19
Product Safety
Next Week Trading Opportunities - GILD, ETSY, FCEL, PLUG, SNOW, AAPL
November 21, 2021
With the assistance of AI we can identify patterns, trends, and buy/sell signals. Here are the prospects in the coming week for these six stocks.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
1 Cancer Stock on Buyout Watch in 2022
November 21, 2021
Cardiff Oncology is a prime takeover target heading into 2022.
Via
The Motley Fool
Exposures
COVID-19
Dividend Initiators: A Fertile Ground For Research
November 19, 2021
Only a company with a certain type of business can afford to grow dividends over a full business cycle.
Via
Talk Markets
This Cheap Stock Is Paying An Unusually High Yield
November 01, 2021
Gilead has increased their dividend for seven consecutive years. The three-year dividend growth rate of 9.4% shows the level of growth they’re capable of delivering.
Via
Talk Markets
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
October 28, 2021
Gilead Sciences came out with quarterly earnings of $2.65 per share.
Via
Talk Markets
Gilead Files US Application For Bulevirtide In Severe Form Of Viral Hepatitis
November 19, 2021
Gilead Sciences Inc (NASDAQ: GILD) has submitted a marketing application to FDA for bulevirtide for injection (2 mg) for chronic hepatitis delta virus (HDV)...
Via
Benzinga
Exposures
Product Safety
Arcus Stock Rockets To Record As Gilead Unexpectedly Opts Into Cancer Drugs
November 18, 2021
Gilead opted into three programs from a small biotech company, sending shares flying.
Via
Investor's Business Daily
Why Are Arcus Biosciences Shares Trading Higher Today?
November 18, 2021
Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT...
Via
Benzinga
Why Arcus Biosciences Stock Is On Fire Today
November 18, 2021
Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs.
Via
The Motley Fool
2 High-Yield Dividend Stocks That Can Safeguard Your Portfolio Against a Market Crash
November 15, 2021
AbbVie and Gilead Sciences are two top high-yield stocks that could save your portfolio in the event of a marketwide downturn.
Via
The Motley Fool
Topics
Economy
Exposures
Interest Rates
On Target: This Company Says It Delivers Drugs Exactly How You Need Them
November 15, 2021
Photo by Anna Shvets from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
November 12, 2021
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products.
Via
Talk Markets
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &...
Via
Benzinga
Top 5 Stocks To Buy In November 2021
November 09, 2021
High-quality dividend growth stocks are some of the very best stocks in the whole world. They represent equity in world-class businesses that pay reliable, rising dividends.
Via
Talk Markets
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
November 06, 2021
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see...
Via
Talk Markets
Best and Worst Performers Since the COVID Crash Low
November 05, 2021
The major indices have consistently been hitting new record highs over the past few days with the S&P 500 having now more than doubled off the COVID Crash low on March 23, 2020.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
November 05, 2021
Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market. The stakes are high,...
Via
Benzinga
Exposures
COVID-19
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
November 05, 2021
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Exposures
COVID-19
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
November 05, 2021
Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
November 05, 2021
The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil). The Company is developing...
Via
Benzinga
Exposures
COVID-19
Product Safety
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
November 02, 2021
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...
Via
Benzinga
Healthcare Stocks Subject to Government Policy
November 02, 2021
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
5 M&A Stocks to Watch as Goldman Calls for a Big Jump in Deals
November 01, 2021
Goldman Sachs predicts the Democrats' new tax plan could yield positive results for M&A-focused companies. Here are the M&A stocks to watch.
Via
InvestorPlace
Gilead Sciences (GILD) Q3 2021 Earnings Call Transcript
October 29, 2021
GILD earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
October 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Gilead Trims Non-COVID Product Sales Outlook, Though Q3 Earnings Beat Street Estimates
October 29, 2021
Gilead Sciences Inc (NASDAQ: GILD) posted higher-than-expected Q3 earnings on strong demand for its COVID-19 antiviral treatment. Adjusted EPS increased 26% Y/Y to...
Via
Benzinga
Topics
Earnings
Exposures
COVID-19
Financial
Recap: Gilead Sciences Q3 Earnings
October 28, 2021
Gilead Sciences (NASDAQ:GILD) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Gilead Crushes Quarterly Forecasts and Raises Outlook For 2021; But Shares Dip
October 28, 2021
Gilead beat Wall Street's quarterly forecasts and raised its outlook for 2021.
Via
Investor's Business Daily
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.